Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy

Hsin-I Chang; Ming-Kung Yeh
January 2012
International Journal of Nanomedicine;2012, Vol. 7, p49
Academic Journal
No abstract available.


Related Articles

  • Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology. Ait-Oudhia, Sihem; Mager, Donald E.; Straubinger, Robert M. // Pharmaceutics;Mar2014, Vol. 6 Issue 1, p137 

    Liposomal formulations of anticancer agents have been developed to prolong drug circulating lifetime, enhance anti-tumor efficacy by increasing tumor drug deposition, and reduce drug toxicity by avoiding critical normal tissues. Despite the clinical approval of numerous liposome-based...

  • The Treatment of Breast Cancer Using Liposome Technology. Brown, Sarah; Khan, David R. // Journal of Drug Delivery;2012, p1 

    Liposome-based chemotherapeutics used in the treatment of breast cancer can in principle enhance the therapeutic index of otherwise unencapsulated anticancer drugs. This is partially attributed to the fact that encapsulation of cytotoxic agents within liposomes allows for increased...

  • Use of Targeted Liposome-based Chemotherapeutics to Treat Breast Cancer. Khan, David R.; Webb, Maggie N.; Cadotte, Thomas H.; Gavette, Madison N. // Breast Cancer: Basic & Clinical Research;2015 S2, Issue 9, p1 

    The use of nanocarriers such as liposomes to deliver anticancer drugs to tumors can significantly enhance the therapeutic index of otherwise unencapsulated cytotoxic agents. This is in part because of the fact that the phospholipid bilayer can protect healthy sensitive tissue from the damaging...

  • Lipoidal Soft Hybrid Biocarriers of Supramolecular Construction for Drug Delivery. Kumar, Dinesh; Sharma, Deepak; Singh, Gurmeet; Singh, Mankaran; Rathore, Mahendra Singh // ISRN Pharmaceutics;2012, p1 

    Lipid-based innovations have achieved new heights during the last few years as an essential component of drug development. The current challenge of drug delivery is liberation of drug agents at the right time in a safe and reproducible manner to a specific target site. A number of novel drug...

  • Nano-Drugs Based on Nano Sterically Stabilized Liposomes for the Treatment of Inflammatory Neurodegenerative Diseases. Turjeman, Keren; Bavli, Yaelle; Kizelsztein, Pablo; Schilt, Yaelle; Allon, Nahum; Katzir, Tamar Blumenfeld; Sasson, Efrat; Raviv, Uri; Ovadia, Haim; Barenholz, Yechezkel // PLoS ONE;7/6/2015, Vol. 10 Issue 7, p1 

    The present study shows the advantages of liposome-based nano-drugs as a novel strategy of delivering active pharmaceutical ingredients for treatment of neurodegenerative diseases that involve neuroinflammation. We used the most common animal model for multiple sclerosis (MS), mice experimental...

  • Increasing Possibilities of Nanosuspension. Sutradhar, Kumar Bishwajit; Khatun, Sabera; Luna, Irin Parven // Journal of Nanotechnology;2013, p1 

    Nowadays, a very large proportion of new drug candidates emerging from drug discovery programmes are water insoluble and thus poorly bioavailable. To avoid this problem, nanotechnology for drug delivery has gainedmuch interest as a way to improve the solubility problems. Nano refers to particles...

  • Zastosowanie poliuretanów w farmacji -- stan obecny i perspektywy rozwoju. Żółtowska, Karolina; Sobczak, Marcin; Olędzka, Ewa // Polimery;2014, Vol. 59 Issue 10, p689 

    The paper is a literature review concerning the preparation and biomedical properties of polyurethanes for pharmaceutical applications. The basic uses of polyurethanes in pharmacy comprise modern drug formulations (including therapeutical systems, carriers and conjugates). Clinical studies...

  • Auven shows positive results of Seciera for dry eye.  // Optometry Times;Dec2015, Vol. 7 Issue 12, p17 

    The article reports that Auven Therapeutics has announced positive results of its Phase 2b/3 clinical trial that assess the safety and efficacy of its patented nanomicellar formulation of cyclosporine drug Seciera as of December 2015.

  • Adolescents in Clinical Trials. Kapogiannis, B. G.; Mattison, D. R. // Clinical Pharmacology & Therapeutics;Dec2008, Vol. 84 Issue 6, p655 

    Drug development is a lengthy, costly, and complex process, with clinical trials essential for characterizing dosing, safety, and efficacy in treated populations. After regulatory approval, aggressive marketing ensures that most drugs are used by a broad spectrum of ages, genders, races, and...

  • Encore Therapeutics Inc. Announces Successful Proof of Concept Study on Meloxicam Depot Injection.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p309 

    The article reports on the completion of the pre-clinical Proof of Concept (POC) study on Encore Therapeutics Inc.'s (ETI) ETI-511 proprietary phospholipid gel (PG) depot formulation of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam Mobec. It states that the company develops its...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics